Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index Exchange Traded Fund
No trades
Key stats
About Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index Exchange Traded Fund
Home page
Inception date
Jul 27, 2021
Structure
Open-Ended Fund
Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index - CNY - Benchmark TR Gross
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
Tian Hong Asset Management Co., Ltd.
ISIN
CNE100004XJ0
Tightly track the target index, and pursue the minimization of tracking deviation and tracking err. The Fund strives to control the daily average tracking deviation within 0.2%, and the annualized tracking err within 2%.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
No, 517380 doesn't pay dividends to its holders.
517380 shares are issued by Ant Group Co., Ltd. under the brand Tianhong. The ETF was launched on Jul 27, 2021, and its management style is Passive.
517380 expense ratio is 0.60% meaning you'd have to pay 0.60% of your investment to help manage the fund.
517380 follows the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index - CNY - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.